Therapeutic effects of miR-96 antagomir on the keloid OC. (A) Reduction in the miR-96 expression at 1, 3, and 5 weeks following miR-96 antagomir administration. (B) The mean weight of the miR-96 antagomir-treated keloid OC was decreased at week 3 (8%) and week 5 (14%), as compared with the negative control. (C) The relative mRNA levels of COL1A1 and COL3A1 in the keloid OC at week 3 following miR-96 antagomir treatment were significantly decreased (n=10). (D) Relative quantitative analysis of western blotting indicated reduced COL1A1 and COL3A1 protein levels in the miR-96 antagomir-treated group (n=10). (E) Western blots for COL1A1 and COL3A1. (F) Representative images of the keloid OC volume shrinkage at week 4. The dermal architecture was demonstrated using Masson's staining. Loosened and thinner collagen bundles were observed in the miR-96 antagomir-treated group. *P<0.05, **P<0.01 and ***P<0.001 vs. the antagomir negative control group. miR, microRNA; OC, organ culture; COL1A1, collagen subunit 1α1; COL3A1, collagen subunit 3α1.